Search

Your search keyword '"Carpenter, S."' showing total 13 results
Start Over Author "Carpenter, S." Journal haemophilia
13 results on '"Carpenter, S."'

11. Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset

Author

Sharma, R., primary, Dunn, A., additional, Aschman, D., additional, Cheng, D., additional, Wheeler, A., additional, Soni, A., additional, McGuinn, C., additional, Knoll, C., additional, Stein, D. T., additional, Young, G., additional, French, J., additional, Sanders, J., additional, Davis, J. A., additional, Tarantino, M., additional, Lim, M., additional, Gruppo, R., additional, Sidonio, R., additional, Ahuja, S., additional, Carpenter, S., additional, Pipe, S., additional, and Shapiro, A., additional

Published
2017
Full Text
View/download PDF

12. α2-Antiplasmin and its deficiency: fibrinolysis out of balance.

Author

CARPENTER, S. L. and MATHEW, P.

Subjects
*ANTIFIBRINOLYTIC agents, *HEMORRHAGE, *DEFICIENCY diseases, *FIBRINOLYSIS, *BLOOD coagulation, *THROMBOLYTIC therapy
Abstract

Fibrinolysis serves an important role in the process of coagulation, ensuring that clots that are formed in response to injury resolve after the injured tissue is repaired. Fibrinolysis occurs because the protein plasminogen is converted to the active serine protease plasmin by its activating molecules (primarily tissue plasminogen activator). One of the inhibitors of fibrinolysis is α2-antiplasmin, which acts as the primary inhibitor of plasmin(ogen). Congenital deficiency of α2-antiplasmin causes a rare bleeding disorder because of increased fibrinolysis. Despite the rare nature of this disorder, understanding of the actions of α2-antiplasmin and the results of its deficiency has provided the opportunity for better understanding of the fibrinolytic system in both how it affects the risk of bleeding and its impact on other bodily systems. Here, we review the history of the discovery of α2-antiplasmin, our understanding of its genetics and function, and our current knowledge of its congenital deficiency. We also discuss some of the current avenues of investigation into its impact on other diseases and physiological states. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

13. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study

Author

Silvia Riva, Alessandro Gringeri, Hyejin Jo, Erik Berntorp, Angiola Rocino, Bulent Zulfikar, Cindy A. Leissinger, Chiara Biasoli, Lorenzo G. Mantovani, W. Schramm, Kaan Kavakli, Shannon L. Carpenter, Massimo Morfini, F. Fusco, Jerzy Windyga, Bülent Antmen, Paolo Cortesi, Claude Negrier, Gringeri, A, Leissinger, C, Cortesi, Pa, Jo, H, Fusco, F, Riva, S, Antmen, B, Berntorp, E, Biasoli, C, Carpenter, S, Kavakli, K, Morfini, M, N?grier, C, Rocino, A, Schramm, W, Windyga, J, Z?lfikar, B, Mantovani, LORENZO GIOVANNI, Cortesi, P, Négrier, C, Zülfikar, B, Mantovani, L, and Çukurova Üniversitesi

Subjects
Adult, Male, Haemophilia, Pediatrics, medicine.medical_specialty, Inhibitor, Adolescent, Visual analogue scale, Health-related quality of life, Haemophilia A, Hemophilia A, Young Adult, Quality of life, Isoantibodies, Activated prothrombin complex concentrate, Surveys and Questionnaires, Internal medicine, Humans, Medicine, Prospective Studies, Young adult, Child, Prospective cohort study, Genetics (clinical), Aged, Cross-Over Studies, Factor VIII, Hematology, Inhibitors, Prophylaxis, business.industry, General Medicine, Middle Aged, medicine.disease, Crossover study, Child, Preschool, Quality of Life, Female, Prothrombin, business
Abstract

PubMedID: 23731246 Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of joint disease and deterioration of health-related quality of life (HRQoL). To determine the impact of prophylaxis with an activated prothrombin complex concentrate (aPCC) on HRQoL, HRQoL was assessed using the Short-Form (SF)-36 Health Survey and the EQ-5D questionnaire in subjects ?14 years participating in a prospective, randomized, crossover study comparing 6 months of aPCC prophylaxis with 6 months of on-demand therapy. Eighteen of 19 patients completed the survey or questionnaire before and after the on-demand therapy and prophylaxis periods. A general trend towards improved HRQoL after prophylaxis was observed for the 18 evaluable patients in all SF-36 dimensions except for vitality/energy and physical functioning. After prophylaxis, 'good responders,' defined as patients experiencing ?50% reduction in bleeding, exhibited statistically and clinically significant differences in the physical component score (P = 0.021), role - physical (P = 0.042), bodily pain (P = 0.015), and social functioning (P = 0.036). Similarly, the EQ-5D health profile showed a trend towards improvement after prophylaxis in all evaluable patients. Among the good responders, improvements did not differ from those observed after on-demand treatment. EQ visual analogue scale values were slightly improved following prophylaxis for all evaluable patients and the EQ-5D utility index improved in the good responders only. During prophylaxis, patients missed significantly fewer days from school or work because of bleeding than during on-demand treatment (P = 0.01). In conclusion, by significantly reducing bleeding frequency in good responders, aPCC prophylaxis improved HRQoL compared with on-demand treatment. © 2013 John Wiley & Sons Ltd.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results